HIV and hepatitis C testing for people who inject drugs
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study works with syringe service programs to see if offering opt-out HIV and hepatitis C testing helps more people get screened and connected to care. It focuses on programs that do not already offer this testing and are in high-need areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your program must be in an area identified as a high priority by federal health agencies.
- Your program serves at least 300 people each year.
- Your program does not currently offer opt-out HIV/HCV testing.
- Your program agrees to collect and share data on testing and care.
- Key staff members agree to take part in surveys and interviews.
- Your program has not received FOCUS funding or implemented opt-out testing before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a telehealth program can reduce harm and lower HIV risk by helping with safer syringe use. It may help if you have recent syringe exchange use and are not currently on HIV prevention pills.
This study tests how well a program combining telemedicine (virtual doctor visits) and peer support can help prevent HIV among people who inject drugs. You'd get trained, attend weekly group sessions, and invite a friend or partner to also take part.
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
This project studies how to improve offering and completing HIV (and hepatitis C) tests in opioid treatment programs. It may help increase timely follow-up and linkage to care when results are positive.
This study provides safer, low-dead-space syringes to people who inject drugs to help reduce the spread of infections like HIV and hepatitis C. It is designed for people in low- and middle-income countries who use needle exchange programs.
This trial tests a convenient way to screen people who use drugs or are in vulnerable situations for hepatitis B, C, and HIV using rapid tests and a liver scanner. The goal is to see if offering these tests in community settings (like shelters or mobile clinics) is acceptable and works well.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.